You just read:

EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

News provided by

Regeneron Pharmaceuticals, Inc.

Mar 19, 2018, 07:00 ET